Navigation Links
Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
Date:4/16/2013

SHENZHEN, China, April 16, 2013 /PRNewswire/ -- Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, today announced the achievement of the primary endpoint in the pivotal, registrational Phase 2 CHIPEL trial of Chidamide (Epidaza®), an orally active benzamide type of class I-selective histone deacetylase (HDAC) inhibitor. The NDA filing has been granted as an accelerated review by the China Food and Drug Administration (CFDA).

The CHIPEL trial was an open-labeled, single arm study in Chinese population to evaluate efficacy and safety of orally administrated Chidamide with relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, who had failed at least one prior systemic therapy. The CHIPEL trial surpassed an objective response rate (ORR) of at least 27%, the primary endpoint as a prior established agreement with CDE of CFDA, evaluated by both investigators and independent review committee. The trial results will be presented on June 3, 2013 at the Lymphoma and Plasma Cell Disorders Poster Discussion Session in the 2013 ASCO Annual Meeting, to be held in Chicago, USA.

"We are pleased to confirm that the trial has achieved its primary endpoint although the pathological subtypes of PTCL in Chinese population are significantly different from that in North America and Europe, where two FDA approved PTCL drugs, Pralatrexate and Romidepsin, were tested," stated Xian-Ping LU, Ph.D., Chief Executive Officer and Chief Scientific Officer of Chipscreen Biosciences Ltd. "We also expect efficacy and safety findings of Chidamide in combination with chemotherapeutic regimen for NSCLC in an ongoing Phase II trial."

About Chidamide

Chidamide is a Class I HDAC inhibitor being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effects are thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis, inhibition of epithelial to mesenchymal transition (EMT, a process that is highly relevant to tumor cell metastasis and drug resistance), induction of tumor specific antigen and antigen-specific T cell cytotoxicity, enhancement of NK cell anti-tumor activity, induction of differentiation, and resensitization of tumor cells that have become resistant to anticancer agents such as platinums, taxanes and topoisomerase II inhibitors.

About Chipscreen

Chipscreen is a leading integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages. The company was established as Sino-foreign joint venture in 2001.

For Chipscreen Biosciences

Rebecca Hai , (86)-755-26957317
Investor Relations
rebeccai_hai@chipscreen.com


'/>"/>
SOURCE Shenzhen Chipscreen Biosciences, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
2. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
3. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
4. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
5. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
6. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
11. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
(Date:4/26/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) is ... , Pharm D., to Vice President of Education and ... Hagerman will continue to lead and oversee Diplomat University, ... education and training to Diplomat employees and external professionals ... University also houses the quality assurance department, which focuses ...
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
Breaking Medicine Technology:
(Date:5/1/2016)... ... May 01, 2016 , ... Women’s Excellence has ... mothers a better understanding of what to expect after they deliver. The guide ... postpartum, · The blues and depression, · Breastfeeding beyond postpartum · Baby basics ...
(Date:4/30/2016)... ... April 30, 2016 , ... Create ... Abstract users can distort and manipulate three-dimensional shapes with ease all within ... ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture ...
(Date:4/30/2016)... (PRWEB) , ... April 30, ... ... by CBC News on April 4th, 2016 questioned the use of the ... to EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... , ... On Tuesday, April 26, 2016 members of the HomeTown Health network, ... Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, ... credit to individuals and corporations which donate directly to a “rural hospital” in Georgia, ...
Breaking Medicine News(10 mins):